-
1.发明授权
公开(公告)号：EP3153165B1
公开(公告)日：2020-05-06
申请号：EP15803906.5
申请日：2015-06-03
发明人： ZHONG, Wu , LI, Song , CAO, Shuang , CAO, Ruiyuan , XIAO, Junhai , ZHOU, Xinbo , LI, Xingzhou
IPC分类号： A61K31/395 , C07D405/14 , C07D405/00 , C07D491/18
-
公开(公告)号：EP2955174B1
公开(公告)日：2019-02-27
申请号：EP13874809.0
申请日：2013-12-10
发明人： LI, Song , XIAO, Junhai , ZHAO, Mingming , ZHONG, Wu , WANG, Lili , ZHENG, Zhibing , XIE, Yunde , LI, Xingzhou , ZHAO, Guoming , ZHOU, Xinbo , WANG, Xiaokui , CHEN, Wei
IPC分类号： C07D307/33 , A61K31/635 , A61P31/04
-
公开(公告)号：EP3085701B1
公开(公告)日：2019-02-20
申请号：EP14872369.5
申请日：2014-12-19
发明人： ZHONG, Wu , LI, Song , ZENG, Yanqun , XIAO, Junhai , ZHOU, Xinbo , ZHENG, Zhibing , LI, Xingzhou , WANG, Xiaokui , WANG, Lili
IPC分类号： C07D401/04 , C07D417/06 , A61K31/506 , A61K31/454 , A61P35/00 , A61P25/28 , A61P37/06 , A61P31/00
-
4.发明授权DERIVATES OF SUBSTITUTED TARTARIC AICD AND USAGE FOR PREPARATING BETA SECRETASE INHIBITORS 有权取代的酒石酸衍生物的衍生物和用于制备β分泌酶抑制剂的用途
公开(公告)号：EP2116526B1
公开(公告)日：2018-04-18
申请号：EP07702276.2
申请日：2007-02-05
发明人： LI, Song , LIAO, Guochao , XIAO, Junhai , NIE, Aihua , WANG, Lili , ZHONG, Wu , ZHENG, Zhibing
IPC分类号： C07C235/12 , C07D241/04 , A61K31/16 , A61K31/4965 , A61P25/28 , A61P25/00 , A61P43/00 , C07D235/06
CPC分类号： C07C235/16 , C07C235/12 , C07C237/42 , C07C2601/14 , C07D235/06 , C07D295/185
摘要： The present invention relates to compounds represented by formula (I), or isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof: in which each substituent of formula (I) is as defined in the specification. The present invention also relates to preparation methods of compounds represented by formula (I), a pharmaceutical composition comprising compounds represented by formula (I) and usage of compounds represented by formula (I) for treating chronic neurodegenerative diseases such as Alzheimer's disease and other diseases induced by aggregation or deposition of ²-amyloid peptide.
-
5.发明授权THIAZINE AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 有权THAZINAMIDDERIVAT SOWIE PHARMAZEUTISCHE ZUSAMMENSETZUNG UND VERWENDUNG DAVON
公开(公告)号：EP2889293B1
公开(公告)日：2017-04-26
申请号：EP12883262.3
申请日：2012-08-24
发明人： LI, Song , XIAO, Junhai , HAN, Dan , ZHONG, Wu , WANG, Lili , ZHENG, Zhibing , XIE, Yunde , ZHOU, Xinbo , LI, Xingzhou , WANG, Xiaokui , JIANG, Dan , CHEN, Wei , LIU, Hongying
CPC分类号： C07D279/12
-
6.发明公开
公开(公告)号：EP3085700A1
公开(公告)日：2016-10-26
申请号：EP14871647.5
申请日：2014-12-19
发明人： ZHONG, Wu , LI, Song , ZENG, Yanqun , XIAO, Junhai , ZHOU, Xinbo , ZHENG, Zhibing , LI, Xingzhou , WANG, Xiaokui
IPC分类号： C07D401/04 , C07D401/14 , C07D409/14 , A61K31/506 , A61P35/00 , A61P25/28 , A61P37/06 , A61P31/04
CPC分类号： C07D401/04 , A61K31/404 , A61K31/454 , A61K31/4545 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D409/14 , A61K2300/00
摘要： The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.
摘要翻译： 本发明提供了通式I的化合物，其立体异构体，药学上可接受的盐或溶剂合物，其制备方法以及用于制备用于预防和/或治疗由耐药肿瘤或药物引起的疾病或症状的药物的用途 和制备用于预防和/或治疗与肿瘤，神经退行性疾病，异体移植排斥和感染有关的疾病或症状的药物。 优选地，与肿瘤，神经退行性疾病，同种异体移植排斥和感染有关的疾病或症状是由热休克蛋白70（Hsp70）引起的疾病或症状。 本发明化合物用于克服肿瘤耐药性难题，提高肿瘤治疗效果，为临床肿瘤治疗提供了新的医学策略。
-
公开(公告)号：EP2005945A9
公开(公告)日：2009-07-01
申请号：EP06775361.6
申请日：2006-08-11
发明人： LI, Song , ZHONG, Wu , XIAO, Junhai , XIE, Yunde , LI, Xingzhou , CUI, Hao , ZHENG, Zhibing
CPC分类号： A61K31/215 , A61K9/0056 , A61K9/0095 , A61K9/141 , A61K9/1623 , A61K9/1635 , A61K9/1652
摘要： The present invention relates to an oseltamivir phosphate granule and preparation method thereof. The said granule comprises 1.97-19.8 wt.% oseltamivir phosphate, 75.0-97.5 wt.% diluent, 0.1-5.0 wt.% binder, optionally 1.0-5.0 wt.% edible flavouring essence, sweetener and/or edible pigment. It is prepared by using 30-55v/v% aqueous ethanol solution as moistening agent. The granules prepared by the formulation and method according to the present invention have good uniformity and stability and are water-soluble. The administration dosage of the granules can be conveniently selected based on the age and body weight of patients. The oseltamivir phosphate granule is suitable for administering to old people, children and flu gravis patients and those patients that swallow inconveniently or difficultly. The preparation of the granule is simple and low in production cost.
-
公开(公告)号：EP3327010B1
公开(公告)日：2019-12-25
申请号：EP16817233.6
申请日：2016-06-28
发明人： LI, Song , XIAO, Junhai , LYU, Boqun , WANG, Hongqiang , ZHONG, Wu , WANG, Lili , ZHENG, Zhibing , XIE, Yunde , ZHOU, Xinbo , LI, Xingzhou , WANG, Xiaokui
-
公开(公告)号：EP3150576B1
公开(公告)日：2019-07-10
申请号：EP15800371.5
申请日：2015-05-20
发明人： LI, Song , XIAO, Junhai , WANG, Lili , LONG, Long , LI, Wei , LUO, Haoming , LI, Feifei , ZHONG, Wu , ZHENG, Zhibing , XIE, Yunde , LI, Xingzhou , ZHOU, Xinbo , WANG, Xiaokui , CAO, Ruiyuan
IPC分类号： C07C251/86 , C07C249/16 , C07C255/58 , C07C253/30 , A61K31/165 , A61K31/277 , A61P7/06 , A61P7/08
-
公开(公告)号：EP3444240A1
公开(公告)日：2019-02-20
申请号：EP17781872.1
申请日：2017-04-11
发明人： LI, Song , ZHOU, Xinbo , XIAO, Dian , ZHONG, Wu , XIAO, Junhai , ZHENG, Zhibing , LI, Xingzhou , XIE, Yunde , WANG, Xiaokui
IPC分类号： C07D271/12 , C07D413/12 , C07H13/04 , C07H1/00 , A61K31/4245 , A61K31/7056 , A61P25/28 , A61P25/18 , A61P25/16 , A61P25/00 , A61P11/00
摘要： Disclosed in the present invention is a compound of Formula (I), a geometric or optical isomer, a pharmaceutically acceptable salt, a solvate or a polymorph thereof. Also disclosed in the present invention is a composition comprising the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof. Also disclosed in the present invention is a use of the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof in the treatment of a disease or disorder such as a hypoglutamatergic condition, a neurodegenerative disease or respiratory depression, particularly in the treatment of a disease or disorder associated with AMPA receptor.
-
-
-
-
-
-
-
-
-
搜索结果
46 条记录 (耗时 0.021 秒)
